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This paper reports the results of a retrospective study of blood use and blood
loss in 40 neonates during extracorporeal life support (ECLS). Immediately after
onset of bypass 39&plusmn;2.5ml platelets, 59.4&plusmn;6.5ml packed red blood cells (PRBC)
and 15.0&plusmn;5.4ml fresh frozen plasma (FFP) per patient were needed. The average
daily amount given per patient was 49.0&plusmn;3.0ml of platelets and 48.0&plusmn;3.4ml and
9.6&plusmn;3.9ml of PRBC and FFP respectively. The 10 patients who had bleeding
complications received 50.0&plusmn;6.3ml/day of platelets compared to 49.0&plusmn;3.4ml
in the other patients. The majority of blood loss during the entire period of
ECLS was from samples, averaging 43.0 &plusmn; 1.5ml/day. Neck wound drainage,
6.7&plusmn;2.5ml/day per patient, lasted for the entire period.
Introduction
Bleeding is the most common complication seen
during neonatal extracorporeal life support
(ECLS) and has been related to systemic
heparinization and thrombocytopenia.l-4 The
incidence of major bleeding complications is
approximately 15 % , the most severe being
intracranial haemorrhage.5 Bleeding disturbance,
such as oozing from the cannulation site, occurs
in almost all patients on ECLS. Conservative
techniques are currently used to manage bleeding
complications, including lowering the activated
clotting time (ACT) levels and maintaining the
platelet count above 100 000/mm~.4 The decision
to transfuse platelets if the concentration drops
below 100 000/mm3 is arbitrary, but is based on
the observation that bleeding is less when the
amount is kept at this level.6 If severe bleeding
persists there may be a need to disconnect ECLS
either temporarily or permanently.
To reduce the bleeding complications of ECLS
a system utilizing heparin-coated materials or
postcircuit heparin neutralization, eliminating
the need for systemic heparinization, has been
suggested.7-9 We also emphasize the importance
of reducing platelet consumption and improving
platelet haemostatic function during ECLS.
However, before any measurement is applied
it is necessary to analyse the pattern and possible
sources of platelet consumption during ECLS. We
therefore retrospectively studied blood use and
blood loss in 40 neonates who were placed on
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ECLS. This information may indicate not only
how to reduce platelet consumption but also how
to improve haemostasis during ECLS. Improved
haemostasis during ECLS may extend the indica-
tions for ECLS, particularly for premature infants
with respiratory failure who are at high risk of
intracranial haemorrhage.
Materials and methods
The records of 40 neonates requiring ECLS
for respiratory failure at the University of
Michigan Medical Center during the period
from September 1985 to December 1989 were
studied retrospectively. In this period a total
of 152 neonates required ECLS. Forty patients
were selected because they represented a ’normal’
ECLS population. Patients’ diagnoses, outcome
and bleeding complications are given in Table
1. Case selection for ECLS treatment and the
technique of ECLS was as described previously 1
Factors examined included the amount of blood
transfused and the amount of blood loss during
ECLS.
Blood requirements were determined by
recording the volume of platelets, the volume
of packed red blood cells (PRBC) and the
volume of plasma, given as fresh frozen plasma
(FFP) transfused after the onset of ECLS.
Immediately after onset of bypass, one unit of
Table 1 Bleeding complications related to diagnosis
in 40 neonates
MAS = meconium aspiration syndrome; RDS = respiratory
distress syndrome; PFC = persistent fetal circulation, GBSP
= group B Streptococcus pneumonia; CDH = congenital
hernia diaphragmatic herma; PPHN = persistent pulmonary
hypertension in newborns.
platelets was transfused, regardless of platelet
numbers. After that platelets were administered
when the platelet count fell below 100 000/mm3.
Platelet consumption was examined by recording
the volume of platelets transfused to maintain
platelet count above 100 000/mm3. The haema-
tocrit was kept above 45% by the transfusion of
PRBC to maximize the oxygen-carrying capacity
of blood during ECLS. Plasma was administered
as indicated to increase blood volume when the
haematocrit was over 45%. The preparation of
blood products from whole blood was performed
following the guidelines of the American Asso-
ciation of Blood Banks.l° Further processing was
performed at the Blood Bank and Transfusion
Service at the University of Michigan.ll The
amount of PRBC and plasma needed to prime
the circuit was not included in our study. The
priming volume of the extracorporeal circuit
was approximately 300-500ml and was com-
posed of one unit of packed red blood cells
(200ml), 50ml tris(hydroxymethyl)aminomethane
(THAM) solution, 40-50ml of albumin or fresh
frozen plasma, 100 units of heparin and 300mg
calcium gluconate. The haematocrit of the prime
was between 35% and 40%.
The amount of blood loss from the surgical
site was determined by the neck wound drainage
by weighing the surgical dressing hourly. The
amount of blood drawn for sampling was also
examined. All data are reported as mean ± SEM.
Results
Bleeding complications
Ten (25%) patients were considered to have
bleeding complications (Table 1). Two patients
had intracranial haemorrhage diagnosed by
ultrasound, one of whom died. Two had
haematuria, one had significant gastro-intestinal
bleeding and one had cardiac tamponade. Cardiac
tamponade was noticed during ECLS on day 2
by echocardiogram and the condition of the infant
improved after pericardiocentesis was performed.
Four had significant bleeding at the surgical site.
One needed a neck re-exploration on ECLS day
5.
Blood loss
The average wound neck drainage per
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patient was 6.7±2.Sml/day. In patients with
surgical bleeding complications (n=4) it was
44.0±l4.Om1/day. In all other patients (n=36)
neck bleeding was constant at 4.4±l.Om1/day.
Blood loss from blood samples drawn for
haematological and chemical survey was
43.0±l.Sm1/day, 88% of total loss (Figure
1).
Blood requirements
The total daily average blood products
required per patient were 49.0±3.Oml platelets,
48.0±3.4m1 PRBC and 9.6±3.9m1 plasma
Immediately after onset of bypass 39:t2.5ml
of platelets were transfused, regardless of
platelet numbers (Figure 2). The average daily
amount given per patient was 49.0±3.Oml of
platelets to maintain the desired count of
greater than 100 000/mm3. Platelet transfusion
in the 10 patients with bleeding complication
was 50.0±6.3m1 compared to 49.0±3.4m1 in
the other patients. In the first four hours after
the onset of bypass an average of 59.4 ± 6.5ml
PRBC per patient was given (Figure 3). The
need for PRBC transfusion was constant at a
rate of 48±3.4m1/day. In the initial four-hour
period 15.0 ±5.4ml of plasma was given (Figure
4). The average per patient was 9.6±3.9m1/day.
Discussion
Approximately 49ml of platelets are required
daily during ECLS to maintain the platelet count
above 100 000/mm~. There was no significantly
greater amount of platelets transfused to patients
with bleeding complications compared to patients
without bleeding complications. Serious bleeding
complications occurred in 25% of the patients,
causing death in one patient. They had probably
decreased platelet haemostatic function. It is
clear, however, that ECLS caused considerable
platelet consumption in all patients, requiring
daily supplementation. ECLS therefore seems to
affect platelets, and all patients are apparently
at risk of bleeding complications. For this reason
premature infants with respiratory insufficiency
are not considered for ECLS, particularly because
Figure 1 The average volume of blood samples drawn per patient during different time intervals after start of ECLS
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Figure 2 The average amount of platelets per patient transfused during different time intervals after start of ECLS
Figure 3 The average amount of PRBC per patient transfused during different time intervals after start of ECLS
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Figure 4 The average amount of FFP per patient transfused during different time intervals after start of ECLS
of the high risk of intracranial haemorrhage. We
therefore emphasize the importance of decreasing
platelet consumption and of optimizing the pres-
ervation of platelet function. This may safely
extend ECLS treatment to premature infants with
respiratory failure.
The considerable platelet consumption and
decreased platelet function during ECLS may
be caused by two main factors. First,
exposing blood to the artificial surface of
the extracorporeal circuit causes platelet inter-
action with the biomaterials and a ’whole body
inflammatory reaction’. 12-15 Platelet interaction
with biomaterials results in severe reduction of
platelet numbers by platelet deposition on the
materials and by systemic aggregation and seques-
tration of platelets, particularly in the liver.12,13
Coating the surface of the extracorporeal circuit
(with heparin, for example) could improve
biocompatibility and modify platelet depo-
sition. 14 It is also likely that the ’whole body
inflammatory reaction’ seen in cardiopulmonary
bypass (CPB) for open-heart surgery will occur
during ECLS.ls,l6 This whole body inflammatory
reaction is known to affect platelet haemostatic
function. It has been demonstrated that the
administration of proteinase inhibitors during
CPB caused a significant improvement of haemo-
stasis during and after bypass.17-20 It would be
tempting to introduce this treatment for ECLS
as well, although as the patient is exposed to the
circuit for an average of 4-5 days in ECLS, in
contrast to a few hours during CPB, studies are
needed first to examine the pattern of activation
of the plasmatic systems during ECLS.
The second factor, platelet consumption and
dysfunction, may be caused by the relatively
large prime of the circuit. Because the pump
prime does not contain platelets, platelet numbers
drop immediately after the start of ECLS. To
counter this effect an average of 39ml of platelets
were routinely transfused to compensate for the
dilution. This results in a large contribution of less
functional donor platelets affecting haemostasis
during ECLS. A rapid platelet consumption can
be anticipated due to the short lifespan of donor
platelets. This situation is maintained during
ECLS by the need for continuous platelet trans-
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fusions. To decrease or to eliminate the use of
donor platelets because of these negative effects
it is necessary to reduce the prime, which can be
achieved by miniaturization of the circuit.21-23
Next to the frequent platelet transfusions, a
significant amount of PRBC and FFP were also
required during ECLS, particularly in the initial
four-hour period. The need for these substitutions
during the initial period cannot be explained by
blood loss but by the need to treat hypotension
after the onset of ECLS.24 At the initiation of
bypass, patients will often have a transient fall
in mean arterial pressure and during this phase
PRBCs and FFPs are given to keep the mean
arterial pressure above 50mmHg. This tem-
porary hypotension is due to haemodilution and
hypovolaemia as the circulating volume equili-
brates in the patient. Haemodilution is a result
of the prime composition and the large priming
volume as compared to the circulating volume of
a neonate. The prime haematocrit is between 35%
and 40% and additional PRBC transfusions are
needed to increase the haematocrit to 45-50%.
A further result of haemodilution is a decrease in
plasma oncotic pressure which leads to an increase
of extracellular fluid. Furthermore, the release
of vaso-active inflammatory mediators from
blood-surface interaction may also contribute
to acute hypotension by causing vasodilation
and increased vasopermeability.15,16 After the
initial period to stabilize the patient, PRBCs
are given primarily to compensate for blood loss
due to samples, averaging 43ml/day per patient,
drawn for haematological and chemical studies.
PRBC transfusion could be reduced by decreasing
sample size and frequency. On-line control of vital
blood chemistry might be another important tool
to decrease blood sampling.
In summary, neonatal extracorporeal life
support is intrinsically associated with a consid-
erable platelet consumption, requiring frequent
platelet transfusions to maintain a platelet count
greater than 100 000/mm3. Platelet consumption
is caused mainly by two factors: blood-surfaqe
interaction and dilution. The latter factor results
in a large contribution of less vital donor platelets.
These two factors also probably decrease platelet
haemostatic function, resulting in 25% bleeding
complications and exclusion of premature infants
from ECLS treatment. We stress the importance
of decreasing platelet consumption and of pre-
serving platelet haemostatic function to reduce
bleeding complications during ECLS. This may
result in safe ECLS treatment of premature
infants with respiratory failure.
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